Pre-made Ontamalimab benchmark antibody ( Whole mAb, anti-MADCAM1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ontamalimab biosimilar, Whole Mab: Anti-MADCAM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1 in development for the induction and maintenance of clinical remission in patients with ulcerative colitis (UC).
| Products Name (INN Index) | Pre-Made Ontamalimab biosimilar, Whole Mab: Anti-MADCAM1 therapeutic antibody |
|---|---|
| INN Name | Ontamalimab |
| Target | MADCAM1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | 4hcr:MN:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Pfizer,Takeda |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Crohn's disease,Ulcerative colitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MADCAM1 |
| Package |
